Tesaro, Inc. Announces Presentation of Niraparib Clinical Data at the 2013 American Society of Clinical Oncology Annual Meeting
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
WALTHAM, Mass., May 16, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that final results from a Phase 1 trial of niraparib, an inhibitor of poly ADP-ribose polymerase (PARP), will be presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. These results include anti-tumor activity and safety data for 100 patients with solid tumors, including 49 patients with high grade serous ovarian cancer (HGSOC) and twelve patients with breast cancer. Full, updated results relating to the abstract will be provided during the investigators' poster presentation on June 4, 2013.
Help employers find you! Check out all the jobs and post your resume.
WALTHAM, Mass., May 16, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that final results from a Phase 1 trial of niraparib, an inhibitor of poly ADP-ribose polymerase (PARP), will be presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. These results include anti-tumor activity and safety data for 100 patients with solid tumors, including 49 patients with high grade serous ovarian cancer (HGSOC) and twelve patients with breast cancer. Full, updated results relating to the abstract will be provided during the investigators' poster presentation on June 4, 2013.
Help employers find you! Check out all the jobs and post your resume.